Jump to content
  • Sign Up
Scott Adams

Biolinerx (Blrx) Reports Celiac Treatment Well Tolerated In Phase 1/2 Study - Streetinsider.com (Subscription)

Rate this topic

Recommended Posts

BioLineRx (BLRX) Reports Celiac Treatment Well Tolerated in Phase 1/2 Study

StreetInsider.com (subscription)

BioLineRx Ltd. (NASDAQ: BLRX) announced today unblinded results from its Phase 1/2 study for BL-7010, a novel polymer for the treatment of celiac disease. The Phase 1/2 study, taking place at Tampere Hospital in Finland, a world-leading site for celiac ...

BioLineRx Announces Results from Phase 1/2 Study for Celiac Treatment Wall Street Journal

BioLineRx reports results from celiac disease drug Phase 1/2 trial (BLRX) Seeking Alpha

BioLineRx Phase 1/2 Trial Of BL-7010 Shows Positive Results RTT News

all 10 news articles »

View the full article

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.


×
×
  • Create New...